Clinical and hormonal effects of a long‐acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome

Cancer

Volumn 59, Issue 9, 1987, Pages 1654-1660

  Souquet, Jean‐Christophe ^a   Sassolas, Geneviève ^b   Forichon, Jacques ^a   Champetier, Pascal ^a   Partensky, Christian ^a   Chayvialle, Jean‐Alain ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b Hospices Civils de Lyon   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CISPLATIN; DOXORUBICIN; FLUOROURACIL; LOPERAMIDE; METHYSERGIDE; OCTREOTIDE; RANITIDINE; SOMATOSTATIN; STREPTOZOCIN;

APUDOMA; CARCINOID SYNDROME; CLINICAL ARTICLE; DRUG DOSE; DRUG EFFICACY; DRUG MONITORING; DRUG THERAPY; ENDOCRINE SYSTEM; GASTRINOMA; GLUCAGONOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; THERAPY;

ADULT; AGED; CARCINOID TUMOR; FEMALE; GASTRIC JUICE; GASTRINS; GLUCAGONOMA; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OCTREOTIDE; PANCREATIC NEOPLASMS; SOMATOSTATIN; SUBSTANCE P; ZOLLINGER-ELLISON SYNDROME;

EID: 0023259848     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19870501)59:9<1654::AID-CNCR2820590922>3.0.CO;2-C     Document Type: Article

References (34)

1. Somatostatin
2. Somatostatin and the gastrointestinal tract
3. Somatostatin inhibition of insulin and gastrin hypersecretion in pancreatic islet‐cell carcinoma
4. Somatostatin inhibits diarrhea in carcinoid syndrome
5. Effect of somatostatin on diarrhoea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera
6. The metabolic clearance and plasma half disappearance time of exogenous somatostatin in man
7. Rebound effect after somatostatin treatment in Verner Morrison syndrome
8. Editorial. Somatostatin: Hormonal and therapeutic roles
9. The effect of somatostatin analogs on secretion of growth, pancreatic, and gastrointestinal hormones in man
10. Suppression of pancreatic endocrine tumour secretion by long‐acting somatostatin analogue
11. SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
12. Treatment of metastasising GRF‐producing tumour with a long‐acting somatostatin analogue
13. Malignant insulinoma: Effects of somatostatin analog (compound 201–995) on serum glucose, growth, and gastroenteropancreatic hormones
14. Pancreatic cholera syndrome: Effect of a synthetic somatostatin analog on intestinal water and ion transport
15. Effect of a long‐acting somatostatin analogue (SMS 201–995) in a patient with pancreatic cholera
16. Long‐term treatment of acromegaly with the somatostatin analogue SMS 201–995
17. Treatment of malignant carcinoid syndrome: evaluation of a longacting somatostatin analogue
18. Immunoreactive somatostatin and vasoactive intestinal peptide in the digestive tract of cats
19. Hormonal and metabolic effects of near physiological increase of plasma immunoreactive somatostatin 14
20. Jejunal secretory effect of intraduodenal food in humans: A comparison of mixed nutrients, proteins, lipids, and carbohydrates
21. Tumors of the endocrine pancreas
22. Gut hormone secreting tumours
23. New somatostatin molecule for management of endocrine tumours
24. Treatment of relapsing bleeding peptic ulcers with the somatostatin analogue SMS 201–995 in a patient with Zollinger‐Ellison syndrome
25. Longterm treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases
26. Treatment of patients with pancreatic endocrine tumours using a new long‐acting somatostatin analogue: Symptomatic and peptide responses
27. Inhibition of pentagastrin‐stimulated acid secretion after subcutaneous administration of a new somatostatin analogue
28. Prolonged treatment of Zollinger‐Ellison syndrome by long‐acting somatostatin
29. Effectiveness of SMS 201–995, a synthetic long‐acting somatostatin analogue, in treatment of quinidine‐induced hyperinsulinemia
30. Rapid improvement of skin lesions in glucagonomas with intravenous somatostatin infusion
31. Rapid reversal of carcinoid crisis with somatostatin analogue
32. A somatostatin analog inhibits chondrosarcoma and insulinoma tumour growth
33. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones
34. Regression of metastatic vipoma with somatostatin analogue SMS 201–995